Dendritic Cell Therapies for Hematologic Malignancies

Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system’s role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, Matthew, Rosenblatt, Jacalyn, Avigan, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415319/
https://www.ncbi.nlm.nih.gov/pubmed/28480306
http://dx.doi.org/10.1016/j.omtm.2017.03.004
_version_ 1783233501728866304
author Weinstock, Matthew
Rosenblatt, Jacalyn
Avigan, David
author_facet Weinstock, Matthew
Rosenblatt, Jacalyn
Avigan, David
author_sort Weinstock, Matthew
collection PubMed
description Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system’s role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases.
format Online
Article
Text
id pubmed-5415319
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-54153192017-05-05 Dendritic Cell Therapies for Hematologic Malignancies Weinstock, Matthew Rosenblatt, Jacalyn Avigan, David Mol Ther Methods Clin Dev Review Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system’s role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases. American Society of Gene & Cell Therapy 2017-03-18 /pmc/articles/PMC5415319/ /pubmed/28480306 http://dx.doi.org/10.1016/j.omtm.2017.03.004 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Weinstock, Matthew
Rosenblatt, Jacalyn
Avigan, David
Dendritic Cell Therapies for Hematologic Malignancies
title Dendritic Cell Therapies for Hematologic Malignancies
title_full Dendritic Cell Therapies for Hematologic Malignancies
title_fullStr Dendritic Cell Therapies for Hematologic Malignancies
title_full_unstemmed Dendritic Cell Therapies for Hematologic Malignancies
title_short Dendritic Cell Therapies for Hematologic Malignancies
title_sort dendritic cell therapies for hematologic malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415319/
https://www.ncbi.nlm.nih.gov/pubmed/28480306
http://dx.doi.org/10.1016/j.omtm.2017.03.004
work_keys_str_mv AT weinstockmatthew dendriticcelltherapiesforhematologicmalignancies
AT rosenblattjacalyn dendriticcelltherapiesforhematologicmalignancies
AT avigandavid dendriticcelltherapiesforhematologicmalignancies

Ejemplares similares